Novel adgrg2 truncating variants in patients ...
Type de document :
Article dans une revue scientifique: Article original
DOI :
PMID :
URL permanente :
Titre :
Novel adgrg2 truncating variants in patients with x-linked congenital absence of vas deferens
Auteur(s) :
Pagin, Adrien [Auteur]
Toxicologie et Génopathies [CHRU Lille]
Bergougnoux, Anne [Auteur]
Girodon, Emmanuelle [Auteur]
Reboul, Marie-Pierre [Auteur]
Willoquaux, Christelle [Auteur]
Kesteloot, Maryse [Auteur]
Raynal, Caroline [Auteur]
Bienvenu, Thierry [Auteur]
Humbert, Mathilde [Auteur]
Lalau, Guy [Auteur]
Bieth, Eric [Auteur]

Toxicologie et Génopathies [CHRU Lille]
Bergougnoux, Anne [Auteur]
Girodon, Emmanuelle [Auteur]
Reboul, Marie-Pierre [Auteur]
Willoquaux, Christelle [Auteur]
Kesteloot, Maryse [Auteur]
Raynal, Caroline [Auteur]
Bienvenu, Thierry [Auteur]
Humbert, Mathilde [Auteur]
Lalau, Guy [Auteur]
Bieth, Eric [Auteur]
Titre de la revue :
Andrology
Nom court de la revue :
Andrology
Numéro :
8
Pagination :
618-624
Éditeur :
Wiley
Date de publication :
2019-12-17
ISSN :
2047-2927
Mot(s)-clé(s) en anglais :
CFTR
obstructive azoospermia
male infertility
congenital absence of vas deferens
ADGRG2
obstructive azoospermia
male infertility
congenital absence of vas deferens
ADGRG2
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Sciences du Vivant [q-bio]/Médecine humaine et pathologie
Sciences du Vivant [q-bio]/Médecine humaine et pathologie
Résumé en anglais : [en]
Congenital absence of vas deferens (CAVD) represents a major cause of obstructive azoospermia and is mainly related to biallelic alteration of the CFTR gene, also involved in cystic fibrosis. Using whole exome sequencing, ...
Lire la suite >Congenital absence of vas deferens (CAVD) represents a major cause of obstructive azoospermia and is mainly related to biallelic alteration of the CFTR gene, also involved in cystic fibrosis. Using whole exome sequencing, we recently identified hemizygous loss-of-function mutations in the Adhesion G Protein-coupled Receptor G2 gene (ADGRG2) as responsible of isolated CAVD in the absence of associated unilateral renal agenesis. The objective of this study was to retrospectively perform ADGRG2 sequencing on a large cohort of patients with CAVD, and 0 or only 1 CFTR defective allele identified after comprehensive testing in order to (a) define more precisely the spectrum and the frequency of ADGRG2 mutations within Caucasian population (b) explore the possibility of co-occurrence of CFTR and ADGRG2 mutations. We collected 53 DNA samples from CAVD patients with 0 (n = 23) or 1 (n = 30) alteration identified after comprehensive CFTR testing in order to perform ADGRG2 sequencing. Twenty patients had normal ultrasonographic renal examination, and renal status was not documented for 33 patients. We identified six new truncating ADGRG2 mutations in 8 patients including two twin brothers: c.251C > G (p.Ser84*), c.1013delC (p.Pro338Hisfs*4), c.1460delG (p.Gly487Alafs*9), c.2096dupT (p.Phe700Ilefs*29), c.2473C > T (p.Arg825*), and c.1731_1839 + 373del (p.Asn578Thrfs*12), which is a 596 base pair deletion affecting the last five bases of exon 21 and the whole exon 22. Five of the eight patients also harbored an heterozygous CFTR mutation which we consider as incidental regarding the high penetrance expected for ADGRG2 truncating variants. The frequency of ADGRG2 truncating mutation was 26% (5/19 unrelated patients) when presence of both kidneys was attested by ultrasonography and 6.1% (2/33) among patients with unknown renal status. Our results confirm the interest of ADGRG2 sequencing in patients with CAVD not formerly related to CFTR dysfunction, especially in the absence of associated unilateral renal agenesis.Lire moins >
Lire la suite >Congenital absence of vas deferens (CAVD) represents a major cause of obstructive azoospermia and is mainly related to biallelic alteration of the CFTR gene, also involved in cystic fibrosis. Using whole exome sequencing, we recently identified hemizygous loss-of-function mutations in the Adhesion G Protein-coupled Receptor G2 gene (ADGRG2) as responsible of isolated CAVD in the absence of associated unilateral renal agenesis. The objective of this study was to retrospectively perform ADGRG2 sequencing on a large cohort of patients with CAVD, and 0 or only 1 CFTR defective allele identified after comprehensive testing in order to (a) define more precisely the spectrum and the frequency of ADGRG2 mutations within Caucasian population (b) explore the possibility of co-occurrence of CFTR and ADGRG2 mutations. We collected 53 DNA samples from CAVD patients with 0 (n = 23) or 1 (n = 30) alteration identified after comprehensive CFTR testing in order to perform ADGRG2 sequencing. Twenty patients had normal ultrasonographic renal examination, and renal status was not documented for 33 patients. We identified six new truncating ADGRG2 mutations in 8 patients including two twin brothers: c.251C > G (p.Ser84*), c.1013delC (p.Pro338Hisfs*4), c.1460delG (p.Gly487Alafs*9), c.2096dupT (p.Phe700Ilefs*29), c.2473C > T (p.Arg825*), and c.1731_1839 + 373del (p.Asn578Thrfs*12), which is a 596 base pair deletion affecting the last five bases of exon 21 and the whole exon 22. Five of the eight patients also harbored an heterozygous CFTR mutation which we consider as incidental regarding the high penetrance expected for ADGRG2 truncating variants. The frequency of ADGRG2 truncating mutation was 26% (5/19 unrelated patients) when presence of both kidneys was attested by ultrasonography and 6.1% (2/33) among patients with unknown renal status. Our results confirm the interest of ADGRG2 sequencing in patients with CAVD not formerly related to CFTR dysfunction, especially in the absence of associated unilateral renal agenesis.Lire moins >
Langue :
Anglais
Comité de lecture :
Oui
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
CHU Lille
Institut Pasteur de Lille
Université de Lille
Institut Pasteur de Lille
Université de Lille
Date de dépôt :
2022-02-02T10:24:17Z
2022-11-29T15:13:34Z
2022-11-29T15:13:34Z
Fichiers
- Pagin et al.pdf
- Version finale acceptée pour publication (postprint)
- Accès libre
- Accéder au document